- Home
- CNTX vs IXHL Comparison
CNTX vs IXHL Comparison
Compare CNTX & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- IXHL
- Stock Information
- Founded
- CNTX 2015
- IXHL 2001
- Country
- CNTX United States
- IXHL Australia
- Employees
- CNTX N/A
- IXHL N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- IXHL
- Sector
- CNTX Health Care
- IXHL
- Exchange
- CNTX Nasdaq
- IXHL Nasdaq
- Market Cap
- CNTX 78.0M
- IXHL 78.7M
- IPO Year
- CNTX 2021
- IXHL N/A
- Fundamental
- Price
- CNTX $0.84
- IXHL $1.05
- Analyst Decision
- CNTX Strong Buy
- IXHL
- Analyst Count
- CNTX 5
- IXHL 0
- Target Price
- CNTX $5.50
- IXHL N/A
- AVG Volume (30 Days)
- CNTX 197.0K
- IXHL 163.1M
- Earning Date
- CNTX 08-06-2025
- IXHL 05-15-2025
- Dividend Yield
- CNTX N/A
- IXHL N/A
- EPS Growth
- CNTX N/A
- IXHL N/A
- EPS
- CNTX N/A
- IXHL N/A
- Revenue
- CNTX N/A
- IXHL $98,000.00
- Revenue This Year
- CNTX N/A
- IXHL $2,538.49
- Revenue Next Year
- CNTX N/A
- IXHL $249.95
- P/E Ratio
- CNTX N/A
- IXHL N/A
- Revenue Growth
- CNTX N/A
- IXHL N/A
- 52 Week Low
- CNTX $0.49
- IXHL $0.08
- 52 Week High
- CNTX $2.75
- IXHL $3.12
- Technical
- Relative Strength Index (RSI)
- CNTX 64.84
- IXHL 65.21
- Support Level
- CNTX $0.82
- IXHL $0.21
- Resistance Level
- CNTX $0.87
- IXHL $1.66
- Average True Range (ATR)
- CNTX 0.07
- IXHL 0.15
- MACD
- CNTX 0.01
- IXHL 0.11
- Stochastic Oscillator
- CNTX 58.27
- IXHL 57.99
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.